New Cancer Drug Shows Breakthrough Results in Clinical Trials
Daraxonrasib has emerged as a significant development in the treatment of stage 4 pancreatic cancer, with clinical trials showing it can double patient survival time from 6.7 months to 13.2 months. According to Dr. Mark Lewis, director of gastrointestinal oncology at Intermountain Health, the medication represents a shift in targeting the KRAS mutation, providing a … Read more